| Document Date: 2015-05-27 04:50:40
Open Document File Size: 274,79 KBShare Result on Facebook
City Berlin / NOX / London / Boston / / Company First Data / NOXXON Pharma / Ligand / / Continent Europe / / Country Germany / United States / / Event FDA Phase / Person Communication and Meetings / / IndustryTerm biopharmaceutical / / MedicalCondition specifically diabetic nephropathy / proteinuria / glioma / diabetes / relapsed/refractory Multiple Myeloma / cancer-related anemia / chronic disease / inflammatory cells / ESA-hyporesponsive anemia / inflammation / anemia / glioblastoma / / MedicalTreatment chemotherapy / radiotherapy / dialysis / / Organization European Renal Association / European Dialysis and Transplant Association / NOX-H94 administration / seen following NOX-H94 administration / / Person Matthias Baumann / / Position Chief Medical Officer / mediator / / Product E36 / A12 / Spiegelmer® NOX / NOX / / Technology pharmacokinetics / antibodies / chemotherapy / ESA / dialysis / /
SocialTag |
PRESS RELEASE First Data from NOXXON’s NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference Berlin, Germany and Boston, USA - May 29, NOXXON Pharma a